Skip to main content
SpringerLink
Log in

Perspective: Effect of rosiglitazone on cardiovascular outcomes

  • Editor’s Commentary
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Nissen SE, Wolski K:Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.N Engl J Med 2007,356:2457–2471.

    Article  PubMed  CAS  Google Scholar 

  2. Bradburn MJ, Deeks JJ, Berlin JA, Localio AR:Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events.Stat Med 2007,26:53–77.

    Article  PubMed  Google Scholar 

  3. Avandia [package insert]. Philadelphia, PA: GlaxoSmith-Kline; 2007. Available at http://www.fda.gov/cder/foi/label/ 2007/021071s023lbl.pdf. Accessed May 15, 2007.

  4. Nissen SE, Wolski K, Topol EJ:Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.JAMA 2005,294:2581–2586.

    Article  PubMed  CAS  Google Scholar 

  5. Dormandy JA, Charbonnel B, Eckland DJ, et al.:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglit Azone Clinical Trial In macroVascular Events): a randomised controlled trial.Lancet 2005,366:1279–1289.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiovascular Medicine, The Cleveland Clinic, 9500 Euclid Avenue, Desk F25, 44195, Cleveland, OH, USA

    Steven E. Nissen MD

Authors
  1. Steven E. Nissen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven E. Nissen MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nissen, S.E. Perspective: Effect of rosiglitazone on cardiovascular outcomes. Curr Cardiol Rep 9, 343–344 (2007). https://doi.org/10.1007/BF02938358

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02938358

Search

Navigation